Reviews
Review: Cardiovascular Protection With Pneumococcal Vaccines Remains Unproven
Bonanad et alJournal of clinical medicine

Streptococcus pneumoniae represents a major etiology of community-acquired pneumonia and invasive pneumococcal disease, particularly in older adults and patients with cardiovascular disease, in whom infection can precipitate heart failure, arrhythmias, stroke, myocardial infarction, hospitalization, and death. A narrative review evaluated evidence surrounding pneumococcal vaccination as a cardiorespiratory and cardiovascular prevention strategy, synthesizing data from randomized trials, phase 3 immunogenicity and safety studies, real-world analyses, observational cohorts, and surveillance reports.
While clinical evidence supports vaccine protection against vaccine-type invasive disease and pneumococcal pneumonia, observed associations between vaccination and decreased myocardial infarction risk stem primarily from observational studies and do not establish causality. The 23-valent polysaccharide vaccine utilizes an unconjugated platform that stimulates a T-cell-independent response without generating immunological memory; thus, a higher nominal valency does not necessarily confer superior or more durable clinical effectiveness.
Higher-valency conjugate options PCV20 and PCV21 present differing evidence profiles. PCV20 has phase 3 immunogenicity and safety evidence alongside emerging real-world effectiveness data, whereas PCV21 possesses a broad phase 3 immunogenicity and safety program. Neither conjugate formulation has established superior clinical effectiveness over the other in head-to-head outcome trials, and variations in estimated serotype coverage do not directly translate into quantified clinical protection. Spanish serotype epidemiology remains dynamic, with ongoing disease caused by serotypes in both formulations and recent increases in select legacy serotypes retained in PCV20. The authors conclude that adult pneumococcal vaccination should be integrated into cardiovascular care, with vaccine selection guided by official recommendations, regional serotype epidemiology, age, prior vaccination, disease burden, antimicrobial resistance, and availability rather than valency or immunogenicity metrics alone.
Key Takeaways
- Associations between pneumococcal vaccination and lower myocardial infarction risk derive predominantly from observational cohorts, and a reduction in cardiovascular events remains unproven.
- No head-to-head clinical-outcome study has established superior clinical effectiveness between PCV20 and PCV21, which feature partially overlapping, non-nested serotype compositions.
- A serotype-specific association linking serotypes 3 and 9N to cardiovascular events was reported in an invasive-disease cohort but was not reproduced in a larger pneumococcal pneumonia cohort.
Read the original sourceJournal of clinical medicine
